PAW Capital Corp Trims Stake in Celgene Co. (CELG)

Elias Hubbard
January 14, 2018

The institutional investor held 56,194 shares of the central company at the end of 2017Q3, valued at $2.76 million, up from 49,138 at the end of the previous reported quarter. Bremer Trust National Association who had been investing in Celgene Corp for a number of months, seems to be bullish on the $83.46 billion market cap company. (NASDAQ:CELG) traded up $1.42 on Friday, reaching $106.00. About 244,883 shares traded. Norfolk Southern Corporation (NYSE:NSC) has risen 34.32% since January 13, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Among 5 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 18% are positive. After $1.78 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -1.69% negative EPS growth. The stock of KKR & Co. The stock of HCA Healthcare, Inc. Cantor Fitzgerald has "Buy" rating and $163 target. On Sunday, October 15 the stock rating was maintained by Jefferies with "Buy". (NASDAQ:ALDX) rating on Wednesday, September 13. On Friday, October 27 the stock rating was downgraded by JMP Securities to "Hold". Jefferies has "Buy" rating and $92 target. The rating was maintained by Mizuho with "Buy" on Thursday, June 1. The stock of Celgene Corporation (NASDAQ:CELG) has "Buy" rating given on Thursday, January 14 by Standpoint Research. The stock of Norfolk Southern Corporation (NYSE:NSC) has "Sell" rating given on Tuesday, January 9 by RBC Capital Markets. The firm earned "Outperform" rating on Wednesday, August 12 by Cowen & Co. KeyBanc Capital Markets maintained the stock with "Buy" rating in Thursday, September 21 report. See Aldeyra Therapeutics, Inc.

Since September 14, 2017, it had 0 buys, and 5 sales for $7.73 million activity. 200,000 Aldeyra Therapeutics, Inc.

Five9, Inc., together with its subsidiaries, provides cloud software for contact centers in the United States and internationally. The company was initiated on Tuesday, September 1 by Raymond James. It is developing ADX-102, a small molecule created to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It now has negative earnings. The stock increased 1.36% or $1.42 during the last trading session, reaching $106. Another trade for 5,000 shares valued at $384,946 was sold by Logan Joseph W. RUNKEL JOHN F JR also sold $880,000 worth of Synopsys, Inc. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has declined 18.94% since January 13, 2017 and is downtrending. It has underperformed by 1.13% the S&P500. Its down 0.04, from 0.87 in 2017Q2. It fall, as 32 investors sold KKR shares while 84 reduced holdings. 79 funds opened positions while 239 raised stakes. Patten Gp accumulated 738,583 shares. Sphera Funds accumulated 1.04M shares. Nicholas Investment Partners Ltd Partnership holds 33,344 shares or 0.19% of its portfolio.

Investors sentiment decreased to 0.97 in 2017 Q3. New Mexico Educational Retirement Board reported 0.5% stake. Congress Asset Mngmt Comm Ma invested in 0.01% or 9,834 shares. (NASDAQ:ALDX) for 48,393 shares. Eagleclaw Cap Managment Ltd Com holds 0.94% in Celgene Corporation (NASDAQ:CELG) or 11,360 shares. (NYSE:EGHT). Great West Life Assurance Can holds 0% of its portfolio in 8×8, Inc. It also reduced Biomarin Pharmaceutical Inc (NASDAQ:BMRN) stake by 5,066 shares and now owns 16,934 shares. (NASDAQ:ALDX) for 9 shares. Gofen And Glossberg Lc Il has invested 2.3% of its portfolio in Celgene Corporation (NASDAQ:CELG). Carl Domino Inc reported 27,000 shares. Public Employees Retirement Of Ohio reported 0.46% stake. American Natl Insur Co Tx holds 261,850 shares or 0.19% of its portfolio.

Investors sentiment decreased to 1.17 in 2017 Q3. Celgene Co. The firm has a market capitalization of $83,460.00, a P/E ratio of 25.00, a P/E/G ratio of 0.67 and a beta of 1.77. It dropped, as 44 investors sold CELG shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.87 by $0.04. Hilton Mgmt Llc invested 0.17% of its portfolio in Celgene Corporation (NASDAQ:CELG). Hwg Holdings Lp bought 2,242 shares as the company's stock declined 3.49% while stock markets rallied. Underhill Invest Mngmt Limited Com holds 2,938 shares or 0.23% of its portfolio. Nwq Investment Management Company Llc owns 10.04 million shares or 0.64% of their USA portfolio. Fdx holds 27,078 shares. On Monday, July 17 the stock rating was maintained by RBC Capital Markets with "Buy". (NYSE:HCA). Brandes Ptnrs LP reported 686,968 shares or 1.07% of all its holdings. Fcg Limited Liability Corporation has 208,469 shares for 11.24% of their portfolio. Hl Serv Limited Liability Company has invested 0.02% in Celgene Corporation (NASDAQ:CELG). Seabridge Inv Advsrs Ltd Llc has 4,398 shares. Arcadia Investment Management Corp MI raised its holdings in Celgene by 118.7% in the 3rd quarter. State Street has 12.24 million shares for 0.08% of their portfolio. Bluestein R H & reported 85,458 shares. Peapack Gladstone Fincl has 63,274 shares.

Since August 2, 2017, it had 0 insider buys, and 5 selling transactions for $6.27 million activity. CASEY MICHAEL D also sold $1.29M worth of Celgene Corporation (NASDAQ:CELG) shares. The insider Curran Terrie sold $248,498. $2.42M worth of stock was sold by MARIO ERNEST on Thursday, August 10. On Wednesday, August 2 the insider KAPLAN GILLA sold $1.01M.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. Therefore 55% are positive. Kohlberg Kravis Roberts & Co. had 51 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Thursday, July 6 by Cantor Fitzgerald. UBS maintained the shares of CELG in report on Friday, November 6 with "Buy" rating. On Friday, October 20 the stock rating was downgraded by Citigroup to "Hold". SunTrust maintained it with "Buy" rating and $127.0 target in Monday, January 8 report. The rating was maintained by Barclays Capital on Friday, October 13 with "Equal-Weight". Cantor Fitzgerald maintained the stock with "Buy" rating in Tuesday, August 22 report. The firm has "Hold" rating by Bank of America given on Friday, January 5.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER